TOKYO, May 7 (Reuters) - Japan’s Astellas Pharma said on Wednesday it would suffer further delays in approval for a new version of its key transplant drug after U.S. authorities said they were not ready to approve it for liver transplants.
TOKYO, May 7 (Reuters) - Japan’s Astellas Pharma said on Wednesday it would suffer further delays in approval for a new version of its key transplant drug after U.S. authorities said they were not ready to approve it for liver transplants.
